BIORQ — Biora Therapeutics Share News
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
- $0.00m
- $35.40m
- $0.00m
Brief: Biora Therapeutics Shares Preclinical Data On Oral Delivery Of Biologics At Controlled Release Society 2022
Brief: Biora Therapeutics Announces Successful Completion Of Second Device Performance Study In Human Subjects For Its Targeted Therapeutics Platform
Brief: Biora Therapeutics - On June 6, Received Written Notice From Nasdaq Notifying Company That It Is Not In Compliance With Minimum Bid Price Requirements
Brief: Biora Therapeutics Announces New Patents For Targeted Therapeutics Platform
Brief: Biora Therapeutics Reports Qtrly Net Loss Per Share Of $0.08
U.S. STOCKS ON THE MOVE-Robinhood, chipmakers, oil companies
U.S. STOCKS ON THE MOVE-Apple Inc, GM, Agriculture firms
U.S. STOCKS ON THE MOVE-Uber, Tesla, HP Inc
Progenity slumps 20% after wider-than-expected Q4 loss
Brief: Progenity Provides Corporate Update And Reports Fourth Quarter Loss Per Share Of $0.56
Progenity Inc expected to post a loss of 16 cents a share - Earnings Preview
Progenity Inc expected to post a loss of 16 cents a share - Earnings Preview
Brief: Progenity Strengthens Intellectual Property For Single-Molecule Detection Technology With Additional Patent
Brief: Progenity Announces Acceptance of Two Abstracts on Treatment of Gastrointestinal Disorders at ECCO’22
U.S. STOCKS ON THE MOVE-Snowflake, Tantech, Kroger, C3.ai
Progenity gains on new U.S. patent for molecule detection platform
Brief: Progenity Announces New Patent For Single-Molecule Detection Technology
Progenity slumps as it plans $90 mln secondary offering
Brief: Progenity Receives Over $44 Mln In Warrant Exercises Since August 2021